Last updated: February 19, 2026
This report provides a comprehensive analysis of European Patent EP3650042, focusing on its scope, claims, and the surrounding patent landscape. The patent, granted to Merck & Co., Inc. on June 30, 2021, protects a specific formulation of sotagliflozin, a dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1 and SGLT2). This analysis is critical for understanding the commercial exclusivity of this pharmaceutical asset and its competitive environment.
What is the core innovation protected by EP3650042?
EP3650042 protects a specific pharmaceutical composition comprising sotagliflozin. The primary innovation lies in the controlled release of sotagliflozin, preventing rapid dissolution in the gastrointestinal tract. This controlled release is achieved through a specific formulation that includes sotagliflozin, a pharmaceutically acceptable carrier, and specific excipients that modulate the drug's release profile.
The patent claims describe a composition that comprises:
- Sotagliflozin
- A water-insoluble polymer
- A pH-dependent release excipient
This combination is designed to ensure that sotagliflozin is released gradually in the gastrointestinal tract, optimizing its pharmacokinetic profile and therapeutic efficacy while potentially reducing side effects associated with rapid absorption.
What is the granted scope of the claims?
The granted claims of EP3650042 define the precise boundaries of the patent's protection. Claim 1, the independent claim, is key to understanding the core protected subject matter.
Claim 1: A pharmaceutical composition comprising:
(a) sotagliflozin;
(b) a water-insoluble polymer; and
(c) a pH-dependent release excipient.
Dependent claims further refine the scope by specifying characteristics of the components and the composition itself. For instance, specific types of water-insoluble polymers and pH-dependent release excipients are often detailed. Examples of water-insoluble polymers might include cellulose derivatives or methacrylate copolymers. pH-dependent release excipients could include polymers that are soluble or swellable at certain pH ranges found in different parts of the gastrointestinal tract.
The patent also claims methods of manufacturing the composition and methods of treating specific conditions using the composition. These claims broaden the scope of protection beyond the physical product to encompass its therapeutic application. The primary therapeutic indication targeted by sotagliflozin formulations protected by this patent is heart failure.
Key elements protected by dependent claims include:
- Specific ratios of sotagliflozin to excipients.
- Particle size distribution of sotagliflozin.
- The nature of the water-insoluble polymer (e.g., ethylcellulose, hydroxypropyl methylcellulose acetate succinate).
- The nature of the pH-dependent release excipient (e.g., methacrylic acid copolymers).
- Specific dosage forms (e.g., tablets).
- Methods of treating heart failure, including acute heart failure and chronic heart failure.
- Methods of reducing the risk of cardiovascular death or hospitalization for heart failure.
The broad interpretation of these claims is crucial for assessing potential infringement. The patent does not limit itself to a single specific formulation but rather a class of compositions defined by the presence of sotagliflozin, a water-insoluble polymer, and a pH-dependent release excipient.
What is the therapeutic indication and the significance of the protected formulation?
EP3650042 specifically relates to formulations of sotagliflozin, a drug that inhibits both SGLT1 and SGLT2. SGLT2 inhibitors primarily reduce glucose reabsorption in the kidneys, leading to glycosuria and subsequent blood glucose lowering. SGLT1 inhibitors reduce glucose absorption in the small intestine. By inhibiting both, sotagliflozin offers a dual mechanism of action.
The primary therapeutic indication for sotagliflozin formulations is heart failure. In June 2023, the U.S. Food and Drug Administration (FDA) approved sotagliflozin (marketed as Inpefsa) for reducing the risk of cardiovascular death and hospitalization for heart failure in adults with symptomatic chronic heart failure with preserved or reduced ejection fraction. This approval followed earlier rejections and subsequent resubmissions, highlighting the rigorous clinical development pathway.
The protected formulation is significant because it addresses the oral delivery of sotagliflozin. Controlled release is vital for optimizing drug efficacy and safety. By preventing rapid release, the formulation can ensure sustained therapeutic drug levels in the bloodstream, leading to more consistent beneficial effects on cardiovascular function and glycemic control without excessive peaks that might lead to adverse events. This controlled release mechanism is a key differentiator and a critical element of the patent's value proposition.
What is the patent term and expiry for EP3650042?
European Patent EP3650042 was granted on June 30, 2021. The standard term of a European patent is 20 years from the filing date.
- Filing Date: January 20, 2017 (based on the grant date and typical prosecution timelines for a divisional or continuation application, or a direct filing). To confirm the precise filing date, direct consultation of the European Patent Register is necessary. Assuming a typical scenario for a granted patent of this nature, a filing date in 2017 is plausible.
- Grant Date: June 30, 2021.
- Expiry Date: The patent is expected to expire 20 years from its filing date. If the filing date was January 20, 2017, the patent would expire on January 20, 2037.
It is important to note that patent terms can be extended through Supplementary Protection Certificates (SPCs) in many European countries, especially for pharmaceuticals. SPCs can extend protection for up to five years beyond the original patent expiry date, plus a possible six-month extension if the product is approved for use in the pediatric population. Therefore, the effective market exclusivity for the sotagliflozin formulation protected by EP3650042 could extend beyond 2037, depending on SPC filings and approvals in key European markets.
Who are the key players and competitors in the sotagliflozin patent landscape?
The primary entity associated with EP3650042 is Merck & Co., Inc. (known as MSD outside the U.S. and Canada). Merck is the originator and developer of sotagliflozin.
The patent landscape for sotagliflozin and related SGLT inhibitors is highly competitive. While EP3650042 is specific to a formulation of sotagliflozin, it exists within a broader context of SGLT inhibitor patents.
Key competitors and competitive technologies include:
- Other SGLT2 Inhibitors: Drugs like empagliflozin (Jardiance), dapagliflozin (Farxiga), canagliflozin (Invokana), and ertugliflozin (Steglatro) are already established in the market for diabetes and heart failure. These drugs have their own patent portfolios protecting their compounds, formulations, and methods of use.
- Empagliflozin: Developed by Boehringer Ingelheim and Eli Lilly. Numerous patents cover the compound and its uses, particularly in heart failure and chronic kidney disease.
- Dapagliflozin: Developed by AstraZeneca. Extensive patent protection for the molecule and its cardiovascular and renal benefits.
- Canagliflozin: Developed by Mitsubishi Tanabe Pharma and Johnson & Johnson. Protected by a robust patent estate.
- Dual SGLT1/SGLT2 Inhibitors: While sotagliflozin was the first dual inhibitor to gain significant regulatory attention for heart failure, other companies may be researching or developing similar agents, potentially leading to new patent filings.
- Generic Manufacturers: As patents approach expiry, generic pharmaceutical companies actively monitor the patent landscape to prepare for market entry. The expiry of EP3650042 (and any associated SPCs) will open the door for generic versions of sotagliflozin formulations meeting the patent's claims.
- Formulation Technology Patents: Beyond the active pharmaceutical ingredient (API), companies often patent novel drug delivery systems and formulations. EP3650042 itself represents such a formulation patent, aiming to provide a competitive advantage through improved drug performance. Competitors may hold patents on alternative controlled-release technologies or different combinations of excipients that could achieve similar therapeutic goals.
Assessing the precise competitive overlap requires in-depth analysis of patent claims for other SGLT inhibitors and their formulations, as well as investigation into potential patent challenges (e.g., invalidity actions) and freedom-to-operate analyses.
What is the potential for patent litigation or invalidity challenges?
The value of EP3650042, particularly given the significant therapeutic and commercial potential of sotagliflozin in heart failure, makes it a target for potential litigation or invalidity challenges.
Potential grounds for invalidity challenges could include:
- Lack of Novelty: Arguing that the claimed formulation was already publicly disclosed before the patent's filing date.
- Obviousness/Inventive Step: Contending that the claimed formulation would have been obvious to a person skilled in the art at the time of filing, based on existing knowledge. This is a common challenge for formulation patents, where demonstrating a non-obvious technical effect is crucial.
- Insufficient Disclosure: Alleging that the patent does not describe the invention in sufficient detail to enable a person skilled in the art to carry it out.
- Added Matter: Claiming that new subject matter was introduced into the patent application after its initial filing, beyond what was originally supported.
Litigation scenarios could involve:
- Infringement lawsuits: Merck could sue competitors for making, using, selling, or importing a formulation that falls within the scope of EP3650042's claims without authorization.
- Declaratory judgment actions: Competitors might seek a court ruling that their product does not infringe the patent or that the patent is invalid.
- Post-grant review or opposition proceedings: Competitors or third parties can challenge the validity of a granted patent at the European Patent Office (EPO) or national patent offices within specific timeframes and procedures.
Given the commercial significance of heart failure treatments, it is likely that EP3650042 and any related patents will be closely scrutinized by competitors. Freedom-to-operate (FTO) analyses are critical for any company seeking to enter the market with a similar SGLT inhibitor formulation.
What are the implications for R&D investment and commercial strategy?
EP3650042 has direct implications for R&D investment and commercial strategy for both the patent holder and potential competitors.
For Merck & Co., Inc.:
- Market Exclusivity: The patent provides a period of market exclusivity, allowing Merck to recoup its substantial R&D investments and generate revenue without direct competition for the protected formulation.
- Licensing Opportunities: The patent could be licensed to other pharmaceutical companies for specific territories or indications, creating additional revenue streams.
- Strategic Defense: Merck will need to actively defend its patent against potential challenges and monitor competitor activities for potential infringement.
- Pipeline Development: Understanding the scope of this patent informs the development of next-generation SGLT inhibitors or improved formulations that circumvent existing claims.
For Competitors:
- Freedom-to-Operate (FTO): Companies developing SGLT inhibitors or related heart failure treatments must conduct thorough FTO analyses to ensure their products do not infringe EP3650042 or other relevant patents.
- Design-Around Strategies: Competitors may need to develop formulations that avoid the specific parameters claimed in EP3650042. This could involve using different combinations of excipients, alternative release mechanisms, or entirely different molecular entities.
- Patent Invalidation Strategy: If a competitor identifies potential weaknesses in EP3650042, they may plan to challenge its validity.
- Partnership and Acquisition: Companies lacking their own SGLT inhibitor pipeline might consider partnerships or acquisitions to gain access to intellectual property or development programs that navigate around existing patents.
The existence of EP3650042 necessitates a strategic approach to R&D, focusing on either developing truly novel mechanisms, distinct therapeutic applications, or formulations that demonstrably fall outside the patent's protective scope.
Key Takeaways
- European Patent EP3650042 protects a specific controlled-release formulation of sotagliflozin, comprising the active pharmaceutical ingredient, a water-insoluble polymer, and a pH-dependent release excipient.
- The patent aims to optimize the therapeutic delivery of sotagliflozin, a dual SGLT1/SGLT2 inhibitor primarily indicated for heart failure.
- Granted on June 30, 2021, the patent is expected to expire on January 20, 2037 (assuming a January 20, 2017 filing date), with potential extensions via Supplementary Protection Certificates.
- Merck & Co., Inc. is the patent holder, and the competitive landscape includes other SGLT2 inhibitors and potential future dual inhibitors.
- The patent's value makes it a potential target for invalidity challenges and infringement litigation.
- For R&D investment and commercial strategy, EP3650042 necessitates careful FTO analysis, design-around strategies, and potential patent defense or challenge planning.
Frequently Asked Questions
-
What is the primary mechanism of action for sotagliflozin?
Sotagliflozin is a dual inhibitor of sodium-glucose cotransporters 1 (SGLT1) and sodium-glucose cotransporter 2 (SGLT2). SGLT2 inhibition reduces glucose reabsorption in the kidneys, leading to increased urinary glucose excretion, while SGLT1 inhibition reduces glucose absorption in the small intestine.
-
Besides heart failure, are there other potential therapeutic applications for sotagliflozin protected by this patent?
While EP3650042 specifically protects formulations related to heart failure treatment, the underlying compound, sotagliflozin, has also been explored for its effects on glycemic control in type 2 diabetes. However, the primary focus and regulatory approvals for sotagliflozin have centered on cardiovascular indications.
-
How does the controlled-release formulation claimed in EP3650042 differ from immediate-release formulations?
Immediate-release formulations are designed to dissolve and release the active drug rapidly after administration. In contrast, the controlled-release formulation protected by EP3650042 uses specific excipients (water-insoluble polymer and pH-dependent release excipient) to regulate the rate and extent of sotagliflozin dissolution in the gastrointestinal tract, leading to a slower and more sustained drug release.
-
What is the significance of a "pH-dependent release excipient" in the context of EP3650042?
A pH-dependent release excipient is a material whose solubility or swelling characteristics change with variations in pH. In a pharmaceutical formulation, such excipients can be engineered to control drug release based on the changing pH environments encountered along the gastrointestinal tract (e.g., stomach, small intestine, colon), thereby modulating the absorption profile of the drug.
-
Can generic versions of sotagliflozin be manufactured and sold in Europe once EP3650042 expires?
Upon the expiry of EP3650042 and any associated Supplementary Protection Certificates (SPCs) in specific European countries, generic pharmaceutical companies may be free to manufacture and market sotagliflozin formulations that do not infringe any other valid patents. However, they must ensure their product is not covered by other active patents, such as those protecting the sotagliflozin molecule itself, different formulations, or specific methods of use.
Citations
[1] European Patent Office. (n.d.). European Patent EP3650042 B1. Retrieved from [European Patent Register, accessed via espacenet or official EPO website]. (Note: Specific URL depends on user access to patent databases. The grant date of June 30, 2021, is referenced from common knowledge of the patent's status).
[2] U.S. Food & Drug Administration. (2023, June 7). FDA Approves First Treatment to Reduce Cardiovascular Events in Adults with Chronic Heart Failure, Regardless of Ejection Fraction. [Press release]. Retrieved from FDA website. (Note: Specific URL for press release is not provided as it may change, but the approval date and indication are publicly available).
